Indaptus Therapeutics Reports Q3 2025 Financial Results with $2.98M Net Loss

Indaptus Therapeutics, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of approximately $2.98 million for the three months ended September 30, 2025, compared to a net loss of $3.07 million for the same period in 2024. For the nine-month period, the company incurred a net loss of $12.74 million, up from a loss of $10.89 million in the prior year. The increase in losses is attributed to higher research and development expenses, which rose to $6.50 million from $4.77 million year-over-year, reflecting ongoing clinical trials and product development efforts.

Total operating expenses for the third quarter decreased to $2.65 million from $3.14 million in the previous year, primarily due to a reduction in general and administrative expenses, which fell to $1.13 million from $1.68 million. The company’s cash and cash equivalents stood at $5.83 million as of September 30, 2025, a slight increase from $5.79 million at the end of 2024. However, the total assets decreased to $6.84 million from $7.34 million, indicating a tightening financial position.

In terms of strategic developments, Indaptus Therapeutics executed a reverse stock split of 1-for-28 on June 26, 2025, which allowed the company to regain compliance with Nasdaq's minimum bid price requirement. The company also raised approximately $5.7 million through the issuance of convertible promissory notes and an additional $2.34 million through its At The Market Offering Agreement during the third quarter. These financing activities are crucial as the company continues to seek additional capital to fund its ongoing operations and clinical trials.

Operationally, Indaptus Therapeutics is focused on advancing its product candidates, particularly Decoy20, which is in the early stages of clinical trials. The company has reported a significant increase in its common stock outstanding, rising to 1,641,920 shares as of September 30, 2025, from 428,799 shares at the end of 2024. This increase is indicative of the company's efforts to raise capital through equity financing. The company continues to rely on third-party organizations for clinical trials and manufacturing, which poses risks related to the timely execution of its development plans.

Looking ahead, Indaptus Therapeutics anticipates continued significant cash outflows as it progresses with its clinical trials and commercialization efforts. The company has expressed the need to secure additional financing to support its operations into 2026. Management has indicated that it plans to pursue collaborations, strategic alliances, and further public or private financing to ensure the sustainability of its research and development activities. However, there remains substantial doubt regarding the company's ability to continue as a going concern if it fails to secure the necessary funding.